The devil is in the details, and in this episode of the Eczema Breakthroughs Podcast, we dive deep into smarter skin care for kids with eczema. Dr. Helen Brough (Director: Children’s Allergy Doctors, London), one of the leading experts in eczema treatment, shares step-by-step, evidence-based guidance on moisturizing, bathing, and proactive steroid use. Joining her is Dr. Amber Atwater (Clinical Associate Professor of Dermatology, George Washington University), who unpacks the tricky overlap between allergic contact dermatitis and atopic dermatitis, and why choosing low-allergen products is essential.

References

Emollients to Prevent Pediatric Eczema: A Randomized Clinical Trial

Eczema Care Online

Consumer Preferences, Product Characteristics, and Potentially Allergenic Ingredients in Best-selling Moisturizers

Emollients to Prevent Pediatric Eczema: A Randomized Clinical Trial

Skin Safe 100

Two new studies from the Society for Investigative Dermatology (SID) conference reveal how Staph bacteria use clever strategies to disarm the skin's barrier maintenance function and work with other bacteria to amplify inflammation. Join us for an interview with Dr. Nathan Archer and Dr. Laine Feller from John Hopkins School of Medicine who explain how Staph aureus bacteria uses its superantigen superpower to hinder lipid production ... and more new research from this year's SID meeting.

New treatment alert! The FDA recently approved Tapinarof, applied as a cream, for kids 2 years and up. We ask Dr. Leon Kircik from Icahn School of Medicine, NY, who led the clinical trials about the safety, efficacy and side effects of Tapinarof. And because we are parents too, we ask: How quickly does it work? Can you start/stop it as needed? How easy will it be to access? And more. If you like our podcast, please consider supporting it with a tax deductible donation.

Research discussed

Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children

Maximal usage trial of tapinarof cream 1% once daily in pediatric patients down to 2 years of age with extensive atopic dermatitis

Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials

Tapinarof cream in the treatment of atopic dermatitis in children and adults a systematic review and meta-analysis

Efficacy and safety of Ruxolitinib, Crisaborole, and Tapinarof for mild-to-moderate atopic dermatitis: a Bayesian network analysis of RCTs